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Abstract
Background: Members of the United States Armed Forces receive a series of vaccinations during
their course of service. To investigate the influence of multiple vaccinations on innate immunity, we
measured concentrations of a panel of immunomodulatory and pro-inflammatory cytokines in
serum samples from a group of such individuals.
Results: Significantly increased levels of macrophage inflammatory protein 1α (MIP-1α), MIP-1β
and interleukin 8 (IL-8) were detected. Since these cytokines are known to have anti-human
immunodeficiency virus (HIV) activity, we tested the effect of serum from these individuals on HIV-
1 infectivity and susceptibility of their peripheral blood mononuclear cells (PBMCs) to HIV-1
infection in vitro. Sera from vaccinated military personnel inhibited, and their PBMCs were partially
resistant to, infection by HIV-1 strains tropic to CCR5 (R5), but not to CXCR4 (X4), chemokine
receptor.
Conclusion: These findings demonstrate that increased anti-HIV chemokines can be detected in
vaccine recipients up to 68 weeks following immunization.
Background
Viruses and other pathogens express a variety of proteins
interfering with the host immune responses to counteract
immune surveillance and increase their virulence [1]. The
ability of a pathogen to modulate host response to infec-
tion and the reaction of host cells to such immunomodu-
lation form an environment that can influence concurrent
or subsequent infections by other pathogens [2-5]. A sig-
nificant role in this immunomodulation is played by the
cytokine-chemokine network [6]. For example, infection
with mouse lymphocytic choriomeningitis virus abolishes
replication of the hepatitis B virus, and this process is
mediated by tumor necrosis factor-α and interferon-γ [7].
Co-infection of human lymphoid tissue ex vivo with
human herpesvirus 6 and CCR5-utilizing HIV-1 results in
suppression of HIV infection, a process dependent on her-
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pesvirus 6-mediated upregulation of CC chemokine regu-
lated upon activation in normal T cells expressed and
secreted (RANTES), a natural ligand for CCR5 [8]. Upreg-
ulation of chemokines was also implicated as a primary
mechanism of HIV-1 suppression caused by at least two
other pathogens – measles [9] and GB virus C (GBV-C)
[4]. Similar to co-infections, immunizations, especially
with live vaccines, can change the immune environment
and cytokine profile and may have unexpected effects on
subsequent infection with an unrelated pathogen.
Results and discussion
To test whether immunizations have a long-term effect on
cytokine profile, we measured, using Luminex technol-
ogy, concentrations of a number of immunomodulatory
cytokines in serum samples from six members of the US
military. These individuals received multiple immuniza-
tions including vaccines against smallpox (live vaccinia
virus), anthrax, typhoid, rabies, and influenza during the
15 month period preceding the blood donation (Table 1).
Ten non-military subjects immunized with another live
vaccine, against the yellow fever virus (YF), and 16 non-
vaccinated individuals of matching sex and age served as
controls. The time between the last vaccination and blood
donation for military personnel ranged between 14 and
62 weeks (Table 1). Blood from subjects immunized with
the YF vaccine was collected 16–24 weeks after vaccina-
tion, to allow development of anti-YF immune response
[10] and to match experimental group. Importantly, sub-
jects in this group did not receive any other vaccine within
a period of 60 weeks prior to YF vaccination. Significantly
elevated (compared to unvaccinated group) levels of
CCL3 (MIP-1α), CCL4 (MIP-1β) and CXCL8 (IL-8) were
found in serum samples from vaccinated military person-
nel, but not in recipients of vaccine against yellow fever.
These results were then verified using ELISA (Fig. 1 and
Table 1). No other factor tested, including CCL5
(RANTES, Fig. 1A), CXCL12 (stroma cell-derived factor 1
[SDF-1]), IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-12, IL-15, IL-16,
CXCL10 (IP-10), CXCL9 (monokine induced by IFN-γ
[MIG]), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), interferon gamma (IFN-γ), and tumor
necrosis factor α (TNFα) varied significantly between
multiply vaccinated individuals and unvaccinated sub-
jects.
MIP-1α and MIP-1β are ligands for the CCR5 receptor
[11,12], while IL-8 has been shown to induce CCR5 inter-
nalization [13]. Since CCR5 is a co-receptor for the major-
ity of transmitted HIV-1 strains [14,15], the observed
cytokine profile could provide resistance to HIV-1 infec-
tion through interference with virus interaction with
CCR5. To test this supposition, we analyzed the effect of
sera from vaccinated and control subjects on replication
of R5 and X4 HIV-1 in PBMCs from unvaccinated control
donors. PBMCs from 4 different donors were cultured
without external activation for 3 days to allow physiolog-
ical monocyte-dependent activation of T cells and then
infected with HIV-1ADA (R5 strain) or HIV-1LAI (X4 strain)
adjusted according to reverse transcriptase activity. Serum
from vaccinated military personnel, but not unvaccinated
control subjects, provided partial protection of PBMCs
against infection with R5, but not X4, HIV-1 (Fig. 2). This
result is consistent with previously reported anti-R5 activ-
ity of MIP-1α and MIP-1β at concentrations found in the
sera of vaccinated subjects [16]. Nevertheless, the possibil-
ity remains that some additional soluble factors could
also contribute to the observed protection. Interestingly,
conflicting reports have been published regarding the
effect of CC chemokines on replication of X4 HIV-1
strains, with one group reporting enhancement of X4 HIV-
1 replication [17], whereas the other not confirming this
effect [18]. We did not observe an enhancement of repli-
cation of HIV-1LAI by sera from multiply vaccinated sub-
jects, consistent with the report by Cocchi and colleagues
[18].
We next tested susceptibility of PBMCs from vaccinated
military personnel to HIV-1 infection in vitro. Similar to
the previous experiment, cells were cultured for 3 days
Table 1: Immunization timetable of enrolled military personnel for the 15 month preceding blood collection.
Vaccination (weeks prior to blood collection) Serum chemokines (pg/ml)
donor smallpox anthrax rabies typhoid influenza MIP-1α MIP-1β IL-8 RANTES
1 57 45 14 14 14 671 981 346 40,866
2 44 nd nd nd nd 874 722 861 63,986
3 60 * * * * 1,219 1,338 669 27,619
4 58 49 ni 49 70, 18 801 791 577 37,571
5 62 ni ni ni ni 760 929 404 48,545
6 62 57, 55, 53 62 55 ni 780 915 348 22,070
*Donor #3 was immunized once against smallpox, once against anthrax, once against typhoid, three times against rabies and once against influenza 
within 60 weeks prior to blood donation (exact dates of immunizations are not available)
nd – no data available; ni – not immunized.BMC Immunology 2006, 7:21 http://www.biomedcentral.com/1471-2172/7/21
Page 3 of 6
(page number not for citation purposes)
without any exogenous activating factor, and then were
infected with R5 (92US660 and ADA), X4 (NL4-3 and
LAI), or dual-tropic (X4R5) (89.6) strain of HIV-1. Results
presented in Figure 3 demonstrate that replication of the
R5 viruses was significantly suppressed in PBMC cultures
derived from military personnel compared to cultures
from unvaccinated control subjects. This difference
became even more pronounced when autologous serum
was present during the in vitro infection (data not shown),
consistent with the presence in these serum samples of
chemokines with CCR5-specific anti-HIV activity (Figs. 1
and 2). No significant differences between cells from vac-
cinated and unvaccinated subjects were observed in infec-
tions with X4 or X4R5 strains of HIV-1 (Fig. 3). Also,
neither R5 nor X4 strains were suppressed in cells from
YFV-immunized subjects (Fig. 3). The protective effect
against R5 HIV-1 strains was lost when the infected cul-
tures were activated with phytohemagglutinin (results not
shown), suggesting that strong activation may overcome
the protective effect of immunization. Surprisingly, analy-
sis of CCR5 expression on CD4 positive cells from multi-
ply vaccinated and control subjects did not reveal
significant differences (results not shown). This result,
however, does not rule out the possibility that the func-
tional activity of CCR5 as an HIV receptor may be
impaired. Further studies will be required to investigate
the mechanisms of this interesting observation.
Suppression of HIV-1 R5 replication by sera from multiply  vaccinated subjects Figure 2
Suppression of HIV-1 R5 replication by sera from 
multiply vaccinated subjects. Replication of R5 (ADA) 
and X4 (LAI) HIV-1 strains was measured in unstimulated 
PBMC cultures from unvaccinated donors in the presence of 
5× diluted serum from multiply immunized (MI) or control 
(C) subjects (6 per group). Results are shown for one repre-
sentative experiment out of four performed with cells from 
different donors. Higher concentration of the serum or 
effect on other viruses could not be tested in this assay 
because of the shortage of the serum available.
Serum chemokine levels in study subjects Figure 1
Serum chemokine levels in study subjects. A. Chemok-
ine levels in serum samples of multiply immunized military 
personnel (mult. imm.) and control unvaccinated subjects 
(non-vacc.) measured by ELISA. Chemokine concentrations 
are shown for each subject of 2 groups (6 vaccinated and 6 
matching unvaccinated individuals). p < 0.001 for MIP-1α and 
MIP-1β, and p < 0.002 for IL-8. B. Chemokine levels were 
measured by ELISA in serum samples of subjects vaccinated 
against Yellow Fever (YFV-imm.) and control individuals 
(non-vacc.). Results are presented for each subject (10 YFV-
immunized and 16 matching controls).BMC Immunology 2006, 7:21 http://www.biomedcentral.com/1471-2172/7/21
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Vaccine against smallpox was the only vaccine received by
all the military personnel involved in this study within
past 15 months, whereas all other immunizations varied
between the subjects. That and the fact that subject 5 did
not get any other immunization but vaccinia (see Table
1), yet his serum showed the same chemokine profile as
serum from other subjects of this group (Fig. 1), suggests
that vaccinia virus may be responsible for the observed
effect. However, the effect of another immunization(s)
received in the more distant past cannot be excluded at the
present time. The observed protection is unlikely to be a
non-specific effect of immunization with a live vaccine,
since vaccination against yellow fever did not alter
cytokine profile or affect sensitivity of recipient's PBMCs
to either R5 or X4 HIV-1 (right panel in Fig. 3). The uni-
formly very low levels of MIP-1α, MIP-1β and IL-8 present
in the serum of control subjects, which had broad racial
diversity, suggests that racial bias (controls were only age
and gender matched) is unlikely to be responsible for the
observed differences.
Conclusion
This study provides evidence that some strong immuno-
gens, or their combination, can cause long-term change in
serum chemokines and induce resistance of PBMCs to
HIV-1 infection. Despite precedence from veterinary med-
icine [19], the observed long-term increase in cytokine
levels induced by vaccination has, to our knowledge,
never been reported in humans. Further studies are neces-
sary to determine which vaccine (or vaccine combination)
is responsible for the protective effect against HIV-1, but
vaccinia is our favorite. Our recent study on PBMCs from
HIV-1 replication in PBMC cultures from vaccinated and unvaccinated donors Figure 3
HIV-1 replication in PBMC cultures from vaccinated and unvaccinated donors. Graphs show the cumulative viral 
production during the 2-week cultivation (mean RT activity ± SD) for each group (6 vaccinated military subjects and 6 matching 
unvaccinated individuals in the left panel; 10 subjects vaccinated against YF and 16 matching unvaccinated individuals in the right 
panel). Student's t test was used to establish statistical significance between groups; *p < 0.05.BMC Immunology 2006, 7:21 http://www.biomedcentral.com/1471-2172/7/21
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another group of military personnel who received vac-
cinia immunization demonstrated a similar restriction of
replication of R5 HIV-1 strains, including a slight
enhancement of suppression of R5 HIV-1 strains in the
presence of autologous serum of multiply immunized
individuals (results not shown). The donors involved in
our study were not tested for the presence of GBV-C. How-
ever, it appears unlikely that all multiply immunized sub-
jects and none of the subjects in the control groups are
GBV-C infected, arguing against the role of GBV-C infec-
tion in the observed phenomenon. Nevertheless, such test
should be included in any of the future studies devoted to
this question. These results warrant a larger study of the
effects of multiple immunizations including vaccinia.
Knowledge of the mechanisms responsible for such stim-
ulation of innate immunity by conventional vaccines may
be used to increase the efficiency of vaccines against HIV-
1 and, if found to involve long-term activation of other




Multiply immunized study volunteers were recruited from
among the US Navy medical personnel. All six individuals
were white males, between 35 and 45 years of age. They
received multiple immunizations in conjunction with
their occupational health program. Six non-military indi-
viduals matched by age (within 3 years) and gender served
as non-vaccinated controls. The ten subjects vaccinated
against yellow fever and the corresponding non-immu-
nized controls were recruited from the GWU Medical
Center Travel Clinic and GWU faculty. A non-immunized
individual was defined for the purpose of the study as a
person who did not receive any vaccination, did not have
any major infection, nor was on immunotherapy within
past 6 months. Yellow fever vaccinees and control groups
were of varied racial background. All individuals involved
in the study traveled quite extensively. Studies in human
subjects were performed in accordance with the Helsinki
Declaration and were approved by the George Washing-
ton University Medical Center Institutional Review Board
(ref. IRB #100537). All subjects provided written consent
for drawing blood.
Cells and viruses
PBMCs (2 × 106 cells/culture) were cultured without add-
ing exogenous activating agents for 3 days, at which point
the culture medium was replaced with diluted serum from
vaccinated or control individuals. After 3 hrs, viral inocu-
lum was added and incubation continued overnight.
Infection was performed with R5 (92US660 and ADA), X4
(NL4-3 and LAI), or dual-tropic (X4R5) (89.6) strains of
HIV-1. The virus inoculum was adjusted according to
reverse transcriptase activity to 1.4 × 105 cpm per 106 cells.
After an overnight incubation, non-attached virus was
washed off in a series of washes with RPMI-1640 supple-
mented with 10% FBS, 2 mM L-glutamine and 10 μg/ml
of gentamicin. In the experiments where exogenous acti-
vation was employed, cells were activated with phytohe-
magglutinin (5 mg/ml for 48 hrs) following the wash step
after the infection and cultured in the presence of IL-2 (20
U/ml).
Chemokine/cytokine analysis
The levels of granulocyte-macrophage colony-stimulating
factor (GM-CSF), interferon gamma (IFN-γ), interleukin
(IL)-1α, IL-1β, IL-2, IL-4, IL-6, CXCL8 (IL-8), IL-12, IL-15,
IL-16, CXCL10 (interferon-inducible protein [IP]-10),
CXCL9 (monokine induced by IFN-γ [MIG]), CCL3 (mac-
rophage inflammatory protein [MIP]-1α), CCL4 (MIP-
1β), CCL5 (RANTES), CXCL12 (SDF-1), and tumor necro-
sis factor (TNF)-α in culture medium were evaluated by
using the multiplex bead-array assays performed on a
Luminex-100 platform (Bio-Plex system – Bio-Rad) as
described previously [9]. Briefly, individual Luminex bead
sets were coupled to cytokine-specific capture antibodies
according to the manufacturer's instructions. The assays
were run by using 1,200 beads/set/well in a total volume
of 50 μl. For each bead set, 61 beads were collected.
Chemokine profiles of MIP-1α, MIP-1β, IL-8 and RANTES
were confirmed by specific ELISAs (R&D Systems, Minne-
apolis, Minnesota) according to the manufacturer's proto-
col.
Flow-cytometric analysis
After an overnight incubation in culture media without
exogenous activation (see Cells and viruses), aliquots of
PBMCs were washed three times and stained with mono-
clonal antibodies (Pharmingen) either as a single staining
or in the following combinations: CD4-fluorescein isothi-
ocyanate (FITC)/CCR5-phycoerythrin (PE), CD8-FITC/
CCR5-PE and CD4-FITC/CXCR4-PE. Staining with corre-
sponding isotype antibodies was used as a control. Flow-
cytometric analysis was performed on BD FACSCalibur.
Obtained data were evaluated using FlowJo (Tree Star,
Inc) software.
Statistical analysis
Student's two-tails paired t test was used to establish sta-
tistical significance between groups.
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